MD Anderson Reports Significant Cancer Research Findings, Including Lung Cancer Immunotherapy Trial Success

MD Anderson Cancer Center researchers announced new oncology findings. The Phase 3 HARMONi trial showed ivonescimab with chemotherapy reduced progression or death risk by 48% in EGFR-mutant non-small cell lung cancer. Additionally, a Phase 1/2 trial demonstrated nearly 77% improvement with fecal microbiota transplantation for immunotherapy-related colitis. These advancements offer new therapeutic avenues for cancer patients.